Regeneron Pharmaceuticals
stock was tumbling after the medicine maker reported lower sales of its Eylea treatment than Wall Street was anticipating for the fourth quarter.
In a preliminary update on its fourth quarter on Monday,
Regeneron
(ticker: REGN) said fourth-quarter sales of Eylea were $1.5 billion. The consensus call among analysts tracked by FactSet was for $1.64 billion, while the year-earlier figure was $1.55 billion.
Vedanta goals to cut back debt, put money into development capex, and concentrate on home market, insulating from international dangers....
Britain's counter-terrorism police arrested 5 males, together with 4 Iranian nationals, on suspicion of terrorism offences over a plot to...
Billionaire investor Warren Buffett stated Saturday that he desires to step down as chief government of Berkshire Hathaway on the finish of the 12...
Avenue Supermarts Ltd, operator of the DMart grocery store chain, reported a big decline of 23.4 per cent in its...
Buoyed by file sale bookings final fiscal, Godrej Properties Ltd. has set a goal to extend its pre-sales by 10%...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
